Mukesh Ambani continued to be the wealthiest Indian with a networth of $83 billion

Kant, speaking at the launch event for CII's report 'Foreign Trade & Investment in India: Unlocking Key Opportunities through Strategic Reforms', further said the country is at the cusp of a transformation

Balkrishna said that the medicines introduced during the press conference have been validated through in-depth in-vitro and in-vivo biological and chemical studies, along with randomised clinical trials

Deshmukh's statements come a day after the Indian Medical Association (IMA) expressed shock over Patanjali's claims of getting WHO certification for Coronil tablets

Yoga guru Ramdev's Patanjali Ayurved had on February 19 said that the Coronil tablet had received certification from the Ayush Ministry as a medicine supporting COVID-19 treatment as per the World Health Organization's certification scheme

In a tweet, the WHO South-East Asia wrote, 'WHO has not reviewed or certified the effectiveness of any traditional medicine for the treatment of COVID-19'

Patanjali had rolled out Coronil for treating novel coronavirus on June 23 in the presence of Union ministers Harsh Vardhan and Nitin Gadkari

Ruchi Soya Q3 results: The edible oil manufacturer, which has Baba Ramdev, his younger brother Ram Bharat and close aide Acharya Balkrishna on its board, posted 20.13 per cent YoY and 12.15 per cent QoQ rise in total income at Rs 4,475.60 crore

Responding to Dabur's claim about maligning its brand and that its honey is NMR passed from Germany and meets Indian standards, the CSE said the company's claim about compliance with Indian laws is no surprise

Baba Ramdev's Patanjali Ayurved paid Rs 4,350 crore to take over Ruchi Soya in 2019. The acquisition helped Patanjali acquire edible oil plants as also soybean oil brands such as Mahakosh and Ruchi Gold

An investment of Rs 1 lakh in Ruchi Soya on June 29, 2020 would have shrunk to Rs 43,778 today, translating into wealth erosion of 56.80% during the period.

Following Q1 earnings, shares of Ruchi Soya opened with a loss of 2.76% today and later touched an intraday low of Rs 683.9, falling 4.99% on BSE against its earlier closing of Rs 719.85. Ruchi Soya stock has fallen after 2 days of consecutive gain

Ruchi Soya board has accepted Acharya Balkrishna's resignation and designated him as non-executive, non-independent director of the company

On June 23, Patanjali Ayurveda had launched 'Coronil' and 'Swasari'. It had claimed that these two drugs could be used for treating COVID-19 and had successfully treated 100 per cent of the COVID-19 patients it was administered to in clinical trials

Catch top stories from the world of business and economy with BusinessToday.In's Biz EOD report

On June 23, Baba Ramdev's Patanjali Ayurved had released \"research-based medicine\" Coronil tablet and Swasari vati, claiming 100 per cent favourable results during clinical trials on COVID-19 infected patients except those on a life support system

Patanjali's Coronil row: The FIR was filed under various sections of the IPC including Section 420 (Cheating) in Jaipur's Jyoti Nagar Police Station against Ramdev, Balkrishna, scientist Anurag Varshney, National Institute of Medical Science (NIMS) Chairman Balbir Singh Tomar and Director Anurag Tomar

The Rajasthan government has clarified that the drug cannot be not used as a medicine in the state without the permission of the Ministry of AYUSH

Ministry of AYUSH has said facts of claim and details of stated scientific study are not known to it; tells company to stop advertising such claims until whole issue is duly examined

Patanjali's coronil kit: According to Patanjali Ayurveda, their team of scientists used the compounds of Ashwagandha, Giloy, and Tusli, suggested by doctors to make Coronil